We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Trade Remedies Authority exists to defend the UK against unfair international trade practices. We investigate whether new trade remedies are needed to prevent injury to UK industries caused by unfair trading practices and make recommendations on appropriate measures to...
Check the tariff classification for a clip-on camera lens attachment made of glass.
Read about talking therapies and counselling for mental health problems.
Find out whether a trade remedy is right for you and how to get advice on your application.
The eyesight rules to pass your driving test and for whenever you're driving.
Find trade remedies notices published from February 2020.
Find out about changes to the Business Investment Relief rules from 6 April 2017.
How to get VAT relief if you’re buying goods because of your disability.
Advice for medical professionals to follow when assessing drivers with visual disorders.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
If you’re a member or a beneficiary of a member of a local government pension scheme, check how the public service pensions remedy (known as McCloud) could affect you.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
Explains testing from 1 April 2024 onwards and sets out the purpose of ongoing testing, who will be eligible to access testing and when tests should be used.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2024) approved the medicine fosdenopterin (Nulibry) to treat the genetic disease Molybdenum Cofactor Deficiency (MoCD) Type A
Actions that trial sponsors should consider to build resilience into clinical trial design
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.